A nurse is caring for a client immediately following endotracheal intubation. The nurse should assess the client for complications by performing which of the following priority action?

A. The medication will open the airways: Albuterol is a bronchodilator that works by relaxing the muscles around the airways, leading to dilation and increased airflow. This action helps to relieve symptoms of asthma or chronic obstructive pulmonary disease (COPD), making it easier for the client to breathe. The nurse should emphasize that opening the airways is a primary function of albuterol, providing immediate relief during breathing difficulties.
B. The medication will stimulate the flow of mucus: Albuterol does not primarily stimulate mucus production; rather, its main role is to relax bronchial smooth muscle and open the airways. While effective airway management may lead to improved mucus clearance due to enhanced airflow, albuterol itself does not directly promote mucus secretion. Thus, this statement does not accurately describe the action of the medication.
C. The medication will decrease coughing episodes: By opening the airways and improving airflow, albuterol can help reduce coughing episodes associated with bronchospasm or airway constriction. When the airways are less constricted, the client is less likely to experience the irritative cough often seen in respiratory conditions like asthma. This is an important point for the nurse to convey to help the client understand the medication's benefits.
D. The medication will prevent wheezing: Albuterol can help prevent or relieve wheezing by relaxing the bronchial muscles and facilitating better airflow. Wheezing often occurs when the airways are narrowed or constricted, and by using albuterol, the client can experience fewer wheezing episodes during respiratory distress. The nurse should explain this aspect to reinforce the medication's role in managing asthma or COPD symptoms.
E. The medication will reduce inflammation: Albuterol is not an anti-inflammatory medication; it primarily functions as a bronchodilator. While it can improve breathing by relaxing airway muscles, it does not directly target inflammation in the airways. Inhaled corticosteroids or other anti-inflammatory medications are typically used to address inflammation. Therefore, this response does not accurately reflect the action of albuterol.

A. pH 7.55, PaCO2 30 mm Hg, PaO2 80 mm Hg, HCO3 24 mEq/L: This ABG finding indicates respiratory alkalosis, as evidenced by the elevated pH and decreased PaCO2. In progressive COPD, clients typically retain carbon dioxide rather than blow it off, so this finding would not be expected in a patient with chronic respiratory issues.
B. pH 7.30, PaCO2 60 mm Hg, PaO2 70 mm Hg, HCO3 30 mEq/L: This is the most consistent finding for a client with progressive COPD. The low pH indicates acidosis, and the elevated PaCO2 suggests respiratory acidosis due to carbon dioxide retention, a common problem in COPD. The elevated HCO3 indicates a compensatory metabolic response, as the body attempts to retain bicarbonate to buffer the acidosis.
C. pH 7.40, PaCO2 40 mm Hg, PaO2 94 mm Hg, HCO3 22 mEq/L: These values indicate a normal ABG, which would not be expected in a client with progressive COPD. Patients with chronic lung disease typically present with acid-base imbalances due to respiratory failure, so this finding suggests the client is not exhibiting the expected complications of COPD.
D. pH 7.38, PaCO2 45 mm Hg, PaO2 88 mm Hg, HCO3 26 mEq/L: Although these findings show mild acidosis, the PaCO2 is within normal limits, indicating that this patient may not be experiencing significant respiratory failure. In advanced COPD, one would expect to see a higher PaCO2 and more pronounced acidosis, making this option less characteristic of a patient with progressive COPD compared to option B.